Coherus Oncology Inc(CHRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.02 | Insider Own | 25.3% | Shs Outstand | 154.5M | Perf Week | -2.92% |
| Market Cap | 0.21B | Forward P/E | - | EPS next Y | 13.97% | Insider Trans | - | Shs Float | 115.4M | Perf Month | 13.68% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.22 | Inst Own | 34.37% | Short Float | 20.72% | Perf Quarter | -6.34% |
| Income | -0.13B | P/S | 4.03 | EPS this Y | 43.24% | Inst Trans | -1.41% | Short Ratio | 24.35 | Perf Half Y | -21.3% |
| Sales | 0.05B | P/B | 3.38 | EPS next 5Y | 28.76% | ROA | -51.1% | Short Interest | 23.92M | Perf YTD | -6.34% |
| Book/sh | 0.39 | P/C | 1.95 | EPS past 3/5Y | 27.14% - | ROE | -178.39% | 52W High | -49.16% ($2.62) | Perf Year | - |
| Cash/sh | 0.68 | P/FCF | - | Sales past 3/5Y | -41.54% -38.41% | ROIC | -115.55% | 52W Low | 22.02% ($1.09) | Perf 3Y | -73.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 25.83% | Gross Margin | 61.86% | Volatility(W/M) | 4.77% 6.38% | Perf 5Y | -91.36% |
| Dividend TTM | - | EV/Sales | 3.03 | Sales Y/Y TTM | -64.32% | Oper. Margin | -307.43% | ATR (14) | 0.08 | Perf 10Y | -95.53% |
| Dividend Ex-Date | - | Quick Ratio | 1.7 | EPS Q/Q | 63.16% | Profit Margin | -256.49% | RSI (14) | 46.93 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.77 | Sales Q/Q | 39.53% | SMA20 | -1.85% ($1.36) | Beta | 0.97 | Target Price | $7.75 |
| Payout | - | Debt/Eq | 0.89 | Earnings | 2026/8/5 | SMA50 | -4.68% ($1.4) | Rel Volume | 0.54 | Prev Close | $1.34 |
| Employees | 147 | LT Debt/Eq | 0.86 | EPS/Sales Surpr. | 12% -0.69% | SMA200 | -15.59% ($1.58) | Avg Volume(3M) | 0.98M | Price | $1.33 |
| IPO | 2014/11/6 | Option/Short | Yes/Yes | Trades | 2125 | Volume | 528,394 | Change | -0.75% |
Company
CHRS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a U.S. biotech company focused on immuno-oncology cancer treatment. The company originated from a biosimilars business, but after divesting its UDENYCA franchise, it has restructured its operations around its nasopharyngeal cancer treatment LOQTORZI (toripalimab) and a new immuno-oncology pipeline. It is headquartered in the United States.
Over the past 1 year, on the lower side
49% below its 1-year high.
CHRS has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +43.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -73.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 34.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SURI 0.01%
QQQS 0.00%
IWC 0.00%
IBBQ 0.00%
OMFS 0.00%It ranks #4 in the industry
Based on market cap of $205M.
CHRS $205M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is CHRS?
CHRS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CHRS?
The market cap of CHRS is approximately $205M, ranking 4,098 within its sector.
What is the 52-week high and low for CHRS?
CHRS has recorded a 52-week high of $2.62 and a low of $1.09.
